Biggest News Aggregation in the World

Page 2 - Stephens Yoder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stephens Yoder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stephens Yoder Today - Breaking & Trending Today

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule

Published: January 10, 2023

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

Source: finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Published: November 2, 2022

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDTElarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continuesFirst subject dosed in PRS-220 phase

Source: finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Published: August 4, 2022

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDTAdjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23Cinrebafusp

Source: finanznachrichten.de

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Published: May 11, 2022

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology

Source: finanznachrichten.de